SCHEMBL18177533

SCHEMBL18177533

CC(=O)c1cccc(-n2c3ccccc3c3ccccc32)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
ATM Q13315 1/20 0.52
POLB P06746 5/20 0.52
ALDH1A1 P00352 4/20 0.49
HPGD P15428 2/20 0.49
MAPT P10636 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
USP2 O75604 1/20 0.47
MYC P01106 1/20 0.47
HSPA1A P0DMV8 1/20 0.47
GAA P10253 1/20 0.47
ALOX15 P16050 1/20 0.47
NR4A1 P22736 1/20 0.47
PTPN7 P35236 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13018688 0.91 HPGD (0.58) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL17851134 0.86 L3MBTL1 (0.55) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL13300206 0.85 HPGD (0.59) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL23242464 0.85 KDM4E (0.56) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL21760733 0.84 FOLH1 (0.62) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL13780976 0.84 L3MBTL1 (0.53) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL13780969 0.83 L3MBTL1 (0.57) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL17850894 0.83 L3MBTL1 (0.52) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL13780982 0.83 KDM4E (0.52) KDM4EL3MBTL1ATMPOLBALDH1A1
SCHEMBL29420600 0.82 L3MBTL1 (0.55) KDM4EL3MBTL1ATMPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9738627-B2 Method for synthesizing 2,6-bis[3′-(N-carbazolyl)phenyl]pyridine compound BEIJING AGLAIA TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2017-08-22 US disclosed
US-9738627-B2 Method for synthesizing 2,6-bis[3′-(N-carbazolyl)phenyl]pyridine compound BEIJING AGLAIA TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2017-08-22 US disclosed
US-20160311799-A1 METHOD FOR SYNTHESIZING 2,6-BIS[3'-(N-CARBAZOLYL)PHENYL]PYRIDINE COMPOUND BEIJING AGLAIA TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2016-10-27 US disclosed
US-20160311799-A1 METHOD FOR SYNTHESIZING 2,6-BIS[3'-(N-CARBAZOLYL)PHENYL]PYRIDINE COMPOUND BEIJING AGLAIA TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311799-A1 METHOD FOR SYNTHESIZING 2,6-BIS[3'-(N-CARBAZOLYL)PHENYL]PYRIDINE COMPOUND DHPS, NISCH, PIN4 KDM4E 1760/4885L3MBTL1 4809/4885ATM 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.